Vanda Pharmaceuticals Inc. (VNDA) announced that its board of directors has unanimously rejected a second acquisition bid by United Kingdom-based Cycle Group Holdings Ltd. ("Cycle Group") wherein the latter proposed to acquire VNDA for $8.00 per share in cash. Shares of Vanda were up 8.3% on Oct 14 following the announcement of the news. Vanda received the second takeover proposal from Cycle Group on Sep 23, 2024. Per management, the second unsolicited, non-binding acquisition proposal was economically iden ...

Board Has Determined That Latest Proposal Is Not in the Best Interests of the Company or Stockholders WASHINGTON, Oct. 14, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. ("Vanda" or the "Company") (Nasdaq: VNDA) today confirmed that it received a second unsolicited, non-binding proposal from Cycle Group Holdings Ltd. ("Cycle Group") to acquire the Company for $8.00 per share in cash. Cycle Group's second proposal was received by Vanda on September 23, 2024. The terms of Cycle Group's proposal are economica ...

Vanda Pharmaceuticals Inc. (VNDA) announced that the FDA issued a complete response letter (CRL) to its new drug application (NDA) seeking approval for its pipeline candidate, tradipitant for the treatment of symptoms in gastroparesis. Shares of the company were down 6.1% on Sept. 19 following the announcement of the news. Marked by delayed gastric emptying, gastroparesis is a serious condition that slows down the stomach's ability to empty its contents. The FDA has not approved any effective medicine for t ...

A regulator's decision drained the market's enthusiasm for the company. The end of the trading week likely can't come fast enough for Vanda Pharmaceuticals (VNDA -6.06%). The commercial-stage biotech's stock took an almost 6% hit on Thursday, following some dispiriting news about one of its investigational drugs. That compared unfavorably to the 1.7% increase in the S&P 500 index during that session. Stomach-disorder drug rejected Bad news about a pipeline product is a fact of life in the biotech and pharma ...

WASHINGTON, Aug. 29, 2024 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that the company will participate in the Wells Fargo 2024 Healthcare Conference in Boston on Friday, September 6, 2024. A corporate presentation is scheduled for 11:00 a.m. Eastern Time. The corporate presentation given at the Wells Fargo 2024 Healthcare Conference may be accessed live on Vanda's corporate website, www.vandapharma.com. Investors should click on the Investors tab and follow the link un ...

Morsa Images Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) is a takeover target. The company received an $8.00 per share bid from Cycle Pharmaceuticals. It also received an upwards-revised bid of $8.50 to $9.00 from Future Pak, that included up to $260 million of potential contingent value right payments, bringing the total consideration to $12.77-$13.27 a share. Despite these two bids, the market did not feel great confidence in either one being accepted, as the stock price never exceeded $7.00 while these bids ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q2 2024 Earnings Conference Call July 31, 2024 4:30 PM ET Company Participants Kevin Moran - Chief Financial Officer Mihael Polymeropoulos - President, Chief Executive Officer & Chairman of the Board Conference Call Participants Charles Duncan - Cantor Fitzgerald Andrew Tsai - Jefferies Operator Thank you for standing by. My name is Meg, and I will be your conference operator today. At this time, I would like to welcome everyone to the Q2 2024 Vanda Pharmaceuticals, ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | --- | --- | |---------------------------------------------------------------------------------------------------|-----------------------------------------------------| | ...

Exhibit 99.1 Vanda Pharmaceuticals Reports Second Quarter 2024 Financial Results ® ® • Revenues for Q2 2024 were $50.5 million, an increase of 6% compared to Q1 2024 and an increase of 10% compared to Q2 2023 • Financial Guidance reinstated for Full Year 2024 • Fanapt approved for the acute treatment of bipolar I disorder; commercial launch initiated in Q3 2024 • PONVORY commercial launch in multiple sclerosis initiated in Q3 2024 • Tradipitant NDA review for gastroparesis ongoing; PDUFA date of September 1 ...

Conference Call and Webcast to Follow Vanda will host a conference call at 4:30 PM ET on Wednesday, July 31, 2024, during which management will discuss the second quarter 2024 financial results and other corporate activities. To participate in the conference call, please dial 1-800-715-9871 (domestic) or 1-646-307-1963 (international) and use passcode 1278669. A replay of the call will be available on Wednesday, July 31, 2024, beginning at 8:30 PM ET and will be accessible until Wednesday, August 7, 2024, a ...